Zinger Key Points
- Aehr Test Systems reports Q2 EPS of 23 cents, versus 19 cents, and revenue of $21.40 million, versus $20.89 million.
- The company states it anticipates an impact to its full-year revenue due to a delay in the timing of new orders.
- Discover Fast-Growing Stocks Every Month
Aehr Test Systems AEHR shares are trading lower in Tuesday's after-hours session following the release of the company's second-quarter earnings report.
What To Know: Aehr Test Systems reported quarterly earnings of 23 cents per share, beating analyst expectations of 19 cents, a 43.75% increase over earnings of 16 cents per share from the same period last year.
The company reported quarterly sales of $21.40 million which exceeded the analyst consensus estimate of $20.89 million, a 44.45% increase over sales of $14.81 million the same period last year.
Total cash and cash equivalents as of Nov. 30 were $50.5 million, compared to $51.0 million at Aug. 31.
Aehr Test Systems revised its expected full-year total revenue to be between $75 million and $85 million, representing growth of 15% to 30% year-over-year. GAAP net income is estimated to be between 20% and 25% of revenue.
The company also stated that full-year revenue will likely be impacted by an anticipated delay in the timing of new orders from current and new customers.
"We had another solid quarter with strong year-over-year growth in revenue and net income as we continue to see increased demand for our wafer level test and burn-in products. Revenue for the quarter was $21.4 million, an increase of 45% year over year, and we generated non-GAAP net income of $6.7 million, slightly over 31% net profit. For the first half of the fiscal year, we grew revenue 65% over the same period last year," said Gayn Erickson, president and CEO of Aehr Test Systems.
AEHR Price Action: Shares of Aehr Test Systems were down 18.5% at $18.21 in the after-hours session at the time of publication Tuesday, according to Benzinga Pro.
Photo: PublicDomainPictures from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.